CONVOTIS has acquisted JMC Group and is entering the Swiss IT market as a platform company and strengthening its position in the managed services and digital platform solutions segment. This acquisition not only provides an
Tags :Alexander Gutmans
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio, a a biotechnology company developing a novel antibody to treat certain forms of cancer. Vertical Bio was founded by Versant
Walder Wyss advises Swiss biotech Alentis Therapeutics in connection with their USD 105m Series C funding to support the development of its lead assets. The funding round was led by Jeito Capital together with Novo
Walder Wyss has advised BC Platforms, an expert of data science solutions for personalized healthcare, drug discovery and life science research, in connection with the CHF 20 million (approx. USD 20 million) growth financing round. This growth
The groupe. id has been acquired by German private equity firm Elvaston Capital Management. Based in La Chaux-de-Fonds and also present in Yverdon-les-Bains, the groupe.id is a renowed Swiss provider of enterprise resource planning
Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
DSM and Firmenich have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. The Dutch specialty chemicals maker has said that this merge with Swiss
